5:38 PM
 | 
Jun 17, 2013
 |  BC Extra  |  Company News

J&J acquiring Aragon for androgen receptor antagonist program

Johnson & Johnson (NYSE:JNJ) will acquire cancer company Aragon Pharmaceuticals Inc. (San Diego, Calif.) for $650 million in cash up front, plus up to $350 million in milestones. J&J will gain Aragon's androgen receptor antagonist program, which includes ARN-509, a second-generation androgen receptor antagonist in Phase II testing...

Read the full 233 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >